AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03819179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum with Bonicell
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
Study NCT03819179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum with Berenew Complex
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
Study NCT03819179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burt's Bees Serum with Ecoskin
Description: This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
Study NCT00005022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT02344927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Clinically Assisted Hydration arm
Description: Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
Study NCT02344927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinically Assisted Hydration arm
Description: Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
Study NCT00005022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00141193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Study NCT01908387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: 100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
Study NCT02091960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Capsules for oral administration
Study NCT02091960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
Study NCT00005022 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00263276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
Study NCT00263276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 5 mg, Once daily, 12 weeks.
Study NCT00263276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 12 weeks.
Study NCT00263276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 20 mg, Once daily, 12 weeks.
Study NCT00263276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Tablets, Oral, 50 mg, Once daily, 12 weeks.
Study NCT00263276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks.
Study NCT00263276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, Oral, >/= 1500 mg, Once daily, 12 weeks.
Study NCT03455959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy/BAL
Description: Participants may receive 3 inhalations (90 ug ea) of albuterol to minimize bronchoconstriction. Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary. 2% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia. 1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia. The bronchoscope is then passed through the vocal cords into the trachea. Throughout the procedure, all participants will have continuous blood pressure, heart rate, and oxygen saturation monitoring. Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals. Once in the lung, aliquots of sterile saline are instilled into two subsegments of the right middle lobe (preferred and if not possible then the right upper lobe) and withdrawn into a trap by gentle suction.
Study NCT04595591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg/kg/min
Description: titration dosing speeds of propofol at 2mg/kg/min
Study NCT04595591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg/kg/min
Description: titration dosing speeds of propofol at 1mg/kg/min
Study NCT04595591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg/kg/min
Description: titration dosing speeds of propofol at 0.5mg/kg/min
Study NCT00942721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT for PPD
Description: A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
Study NCT00691704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide Induction
Description: Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
Study NCT00691704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Maintenance Therapy
Description: Subjects who achieve >partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved > stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle.
Study NCT00555893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight \<=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)
Study NCT00555893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
Study NCT02557464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An eye tracking experiment
Description: Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
Study NCT02557464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An eye tracking experiment
Description: Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
Study NCT02557464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A neuropsychological evaluation
Description: Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
Study NCT02557464 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A neuropsychological evaluation
Description: Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
Study NCT03283748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensors
Description: Wearable sensors will be given to the participants to be worn and movement data will be collected
Study NCT03619330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
Study NCT03619330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
Study NCT03390257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3NT flexible endoscope
Description: The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
Study NCT02465684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unicondylar knee arthroplasty
Study NCT03455959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway Brushing
Description: After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. A second brush will then be introduced into an adjacent airway of the same lobe and gently glided back and forth on the airway epithelium 10 times in 2 different locations as was done with the first brush. The second brush will also be placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
Study NCT01425775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D 25(OH)D
Description: 2000IU/day for 12 months
Study NCT01425775 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
Study NCT03668366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
Study NCT03337750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-PE Therapy
Description: Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
Study NCT01985698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted resection.
Description: Robotic-assisted abdominoperineal resection.
Study NCT01985698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic resection
Description: Laparoscopic abdominoperineal resection
Study NCT03617874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PC4PrEP- Intervention Clinics
Description: PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
Study NCT03617874 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Clinics
Description: The standard of care model is the model approved by the health system for their health care clinics.
Study NCT01930617 — intervention group
Intervention type: PROCEDURE
Intervention: Burr hole surgery with various drainage techniques
Description: Surgical technique~1. Continuous irrigation and drainage~2. Passive subdural drain~3. Active subgaleal drain
Study NCT05447039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Sodium Tablets
Description: intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
Study NCT00625742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Resistance Training
Description: Resistance training sessions twice weekly using Thera-bands.
Study NCT00625742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
Study NCT02781155 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Moxibustion
Description: Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy
Study NCT02062905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02062905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study NCT04610203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25 g Nutralys Pea Protein
Description: To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose +25g Nutralys S85 Plus
Study NCT04610203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 g Nutralys S85 Plus.
Description: To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose+50 g Nutralys S85 Plus .
Study NCT04610203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 50 g Glucose
Description: To determine the glycaemic response, insulinaemic response, GIP response and GLP-1 response to 50g Glucose
Study NCT00625742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 20 mg by mouth (PO) Daily
Study NCT00625742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Description: 90 calories of Juven, twice a day.
Study NCT02948946 — intervention group
Intervention type: PROCEDURE
Intervention: NETest
Description: 5 mL of blood will be drawn from participants for testing.
Study NCT03090217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Physiotherapy
Description: 1) daily pelvic floor muscle training (PFMT).
Study NCT00625742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate >110 beats/min) or resting energy expenditure (REE) > 110% of predicted.
Study NCT00625742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 1200mg/day in three divided doses.
Study NCT01764425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P7435
Description: It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
Study NCT03090217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care (SC)
Description: 1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
Study NCT01764425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P7435
Description: It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
Study NCT00436930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor cell vaccine
Description: Given subcutaneously
Study NCT00436930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study NCT04260035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasoactive Intestinal Polypeptide (VIP)
Description: 20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
Study NCT04260035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
Study NCT00436930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given subcutaneously
Study NCT02749669 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative research
Description: Semi-structured Interviews
Study NCT04545359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alpha-based neurofeedback
Description: Twelve 21-minute sessions (minimum of 1 session and maximum of 3 sessions per week) of auditory alpha-based neurofeedback with the Melomind device developed by myBrain Technologies (France). Recording of felt relaxation, perceived stress level, anxiety level pre-post sessions.~Electrophysiological: Recording of EEG signals on 32 electrodes every two sessions.
Study NCT03252457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles
Study NCT03252457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
Study NCT03252457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
Study NCT02450058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 600 mg/m2 intravenously on day 1, every 21 days for six cycles
Study NCT02450058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 60 mg/m2 intravenously on day 1, every 21 days for six cyles
Study NCT02450058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenously on day 1, every 21 days for six cycles
Study NCT02450058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 90 mg/m2 on day 1, every 21 days for four cycles
Study NCT02450058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
Study NCT02979132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eisensulfat LOMAPHARM 50 mg
Description: oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
Study NCT02979132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject(R)
Description: Single-dose Ferinject(R) administration
Study NCT02979132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron fortified biscuits
Description: consumption of an iron-fortfied biscuit every morning for 90 days
Study NCT04231292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD01
Description: RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
Study NCT04231292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Erythropoiesis Injection (CHO cell)
Description: rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
Study NCT04231292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Human Erythropoiesis Injection (CHO cell)
Description: rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
Study NCT04231292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02489864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin
Study NCT02489864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Study NCT03433404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Mobilization
Description: The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
Study NCT03433404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Massage
Description: For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes